AstraZeneca's Tezspire Recommended for EU Approval in Asthma Treatment
25 Julho 2022 - 03:59AM
Dow Jones News
By Kyle Morris
AstraZeneca PLC said Monday that Tezspire has been recommended
for approval in the EU for the treatment of severe asthma.
The pharmaceutical giant said Tezspire has been recommended by
the Committee for Medicinal Products for Human Use of the European
Medicines Agency as an add-on therapy in patients 12 years and
older with severe asthma who are inadequately controlled with high
dose inhaled corticosteroids plus another medicinal product for
maintenance treatment.
Asthma is a disease that affects around 14 million people living
in the European Union.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
July 25, 2022 02:44 ET (06:44 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024